Very high response rates in previously untreated T-cell prolymphocytic leukaemia patients receiving Alemtuzumab (Campath-1H) therapy.

被引：0
|
作者：
Dearden, CE
Matutes, E
Cazin, B
Ireland, R
Parreira, A
Lakhani, A
Catovsky, D
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Hosp C Huriez, Lille, France
[3] Queen Elizabeth Hosp, Woolwich, England
[4] Inst Oncol, Lisbon, Portugal
[5] Farnborough Hosp, Farnborough, Hants, England
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2378
引用
收藏
页码：644A / 644A
页数：1
相关论文
共 32 条
  • [21] Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Grappo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
    Gallamini, Andrea
    Zaja, Francesco
    Patti, Caterina
    Billio, Atto
    Specchia, Maria Rosaria
    Tucci, Alessandra
    Levis, Alessandro
    Manna, Annunziata
    Secondo, Vicenzo
    Rigacci, Luigi
    Pinto, Antonello
    Iannitto, Emilio
    Zoli, Valerio
    Torchio, Pierfederico
    Pileri, Stefano
    Tarella, Corrado
    BLOOD, 2007, 110 (07) : 2316 - 2323
  • [22] Graft versus host disease-like syndrome after autologous stem cell transplantation in CLL patients treated with a TBI/Cy/alemtuzumab (CAMPATH-1H) high-dose regimen
    Zenz, T
    Dreger, P
    Kröber, A
    Ritgen, M
    Bunies, D
    Dhnerl, H
    Stilgenbauer, S
    BLOOD, 2005, 106 (11) : 822A - 822A
  • [23] THE EFFECT OF CAMPATH(TM)-1H MONOCLONAL-ANTIBODY THERAPY ON THE T-CELL RECEPTOR (TCR) REPERTOIRE OF PATIENTS WITH RHEUMATOID-ARTHRITIS (RA)
    SUNDY, JS
    DENNING, SM
    JACOBS, MR
    STCLAIR, EW
    ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S40 - S40
  • [24] Point-of-care anti-BCMA CAR T-cell therapy induces encouraging response rates in relapsed/refractory multiple myeloma patients mostly with high-risk disease features
    Shkury, Eden
    Fried, Shalev
    Itzhaki, Orit
    Shem-Tov, Noga
    Danylesko, Ivetta
    Yerushalmi, Ronit
    Shouval, Roni
    Nevo, Lee
    Shapira-Frommer, Ronnie
    Nagler, Arnon
    Shimoni, Avichai
    Avigdor, Abraham
    Magen, Hila
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S61 - S61
  • [25] Low CD4 T-cell counts despite low levels of circulating HIV: Insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease
    Albuquerque, Adriana S.
    Foxall, Russell B.
    Cortesao, Catarina S.
    Soares, Rui S.
    Doroana, Manuela
    Ribeiro, Alice
    Lucas, Margarida
    Antunes, Francisco
    Victorino, Rui M. M.
    Sousa, Ana E.
    CLINICAL IMMUNOLOGY, 2007, 125 (01) : 67 - 75
  • [26] High T-Cell Lymphoma Breakpoint 1 (TCL1) Levels Are Associated with Lack of Response and Inferior Outcome Following Fludarabine, Cyclophosphamide, Rituximab (FCR) Frontline Therapy in Patients with Chronic Lymphocytic Leukemia (CLL)
    Schlette, Ellen
    Tam, Constantine S.
    Herling, Marco
    Bueso-Ramos, Carlos
    Wierda, William
    Ferrajoli, Alessandra
    O'Brien, Susan
    Keating, Michael
    Jones, Dan
    BLOOD, 2008, 112 (11) : 726 - 726
  • [27] Long-term CD4+ T-Cell Response in HIV-1-Infected Patients Continuing Combination Antiretroviral Therapy Despite High-Level Viremia and Drug Resistance
    D. Dionisio
    A. Vivarelli
    M. Zazzi
    F. Esperti
    C. Fabbri
    M. Giorgi
    B. Menichini
    European Journal of Clinical Microbiology and Infectious Diseases , 2003, 22 : 69 - 71
  • [28] Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results
    Falchi, Lorenzo
    Jardin, Fabrice
    Haioun, Corinne
    Wrobel, Tomasz
    Joergensen, Judit Meszaros
    Bastos-Oreiro, Mariana
    Mou, Eric
    Martinez-Lopez, Joaquin
    Budde, L. Elizabeth
    Bartlett, Nancy L.
    Zaucha, Jan M.
    Garcia-Sancho, Alejandro Martin
    Shah, Rutanshu
    Rees, Nathan
    McCord, Ron
    Bazeos, Alexandra
    Tandon, Maneesh
    Doral, Michelle
    Troy-Barnes, Ethan
    Nijland, Marcel
    BLOOD, 2023, 142
  • [29] Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.
    Falchi, Lorenzo
    Clausen, Michael
    Offner, Fritz
    De Vos, Sven
    Brody, Joshua
    Linton, Kim M.
    Snauwaert, Sylvia
    Cordoba, Raul
    Wu, Jun
    Bykhovski, Irina
    Wang, Liwei
    Rana, Ali
    Belada, David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) NonHodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study
    Ghosh, Nilanjan
    Townsend, William
    Dickinson, Michael
    Topp, Max
    Tani, Monica
    Santoro, Armando
    Crump, Michael
    Morschhauser, Franck
    Le Gouill, Steven
    Mehta, Amitkumar
    Panchal, Anesh
    Wu, Chun
    Barrett, Martin
    Humphrey, Kathryn
    Qayum, Naseer
    Hutchings, Martin
    BLOOD, 2021, 138
1234